Strategies for Building Early-Stage Pipelines Through External Sources

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Strategies for Accessing Innovation
  • Mergers and Acquisitions
  • Corporate Partnerships
  • Academic Collaborations
• Strategies for Building Early-Stage Pipelines Through Partnering
  • Novel Targets
  • Technology Platforms
• Select Deal Highlights
  • Genentech/Bayhill Therapeutics
  • Boehringer Ingelheim/Vitae Pharmaceuticals
  • GlaxoSmithKline/Concert Pharmaceuticals
  • Sanofi -Aventis/Exelixis
  • Wyeth/Santaris Pharma
  • Alnylam/Takeda
  • Merck/GlycoFi
• Industry Outlook

Tables

• 1. Patent Expirations for Select Blockbuster Drugs
• 2. Select Recent Corporate Partnerships: Discovery and Preclinical
• 3. Select Corporate Partnerships: Early-Stage Clinical Development
• 4. Select Corporate Venture Capital Funds

Figures

• 1. R&D Spending vs. FDA New Molecular Entity Approvals, 1997-2008
• 2. Percentage of Inlicensed Products in Pipelines of Top Pharmaceutical Companies
• 3. Factors Infl uencing Early-Stage Pharma-Biotech Dealmaking